KTTA Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Chartmill - Mentions: IRBT PRPH CLSD MDB ...

What's going on in today's after hours session

12 days ago - By: Chartmill - Mentions: LEG GAME STRO NFE ...

Top movers in Monday's pre-market session

11 days ago - By: Pasithea

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

15 days ago - By: Chartmill - Mentions: BEAT CLSD YCBD ADTX ...

Curious about the stocks that are showing activity after the closing bell on Friday?

15 days ago - By: Chartmill - Mentions: BEAT RUBI CMCT CLSD ...

Top stock movements in today's session.

15 days ago - By: Chartmill - Mentions: HBI BEAT INTC NVDA ...

Friday's session: most active stocks

15 days ago - By: Chartmill - Mentions: PW BEAT CLSD KALA ...

Unusual volume stocks are being observed in Friday's session.

15 days ago - By: Chartmill - Mentions: PW DDC RUBI CLSD ...

Which stocks are moving on Friday?

15 days ago - By: Stocktwits - Mentions: PSIL VXF

Why Did KTTA Stock Soar A Whopping 48% Today?

15 days ago - By: Pasithea

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

16 days ago - By: Chartmill - Mentions: BEAT OMEX TLRY PLAG ...

Top movers in Thursday's after hours session

17 days ago - By: Stocktwits

Pasithea Therapeutics Stock Rockets To Best Day In 4 Years On Massive Share Offering Amid ALS Drug Momentum

17 days ago - By: Chartmill - Mentions: DGLY AMBR MBRX OSS ...

Wednesday's session: top gainers and losers

17 days ago - By: Chartmill - Mentions: PLUG NVDA OPEN AMBR ...

Curious about the most active stocks on Wednesday?

17 days ago - By: Chartmill - Mentions: DGLY CLSD ZYXI GP ...

In today's session, these stocks are experiencing unusual volume.

17 days ago - By: Chartmill - Mentions: DGLY SUPX AMBR MBRX ...

Which stocks are moving on Wednesday?

17 days ago - By: Benzinga

Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today

18 days ago - By: Chartmill - Mentions: ICON BEAT CLSD GP ...

Unusual volume stocks in Tuesday's session

19 days ago - By: Chartmill - Mentions: ICON KEYS JAGX PLAG ...

Get insights into the top gainers and losers of Monday's after-hours session.

19 days ago - By: Chartmill - Mentions: MVO EXAS BEAT FAT ...

Unusual volume stocks are being observed in Monday's session.

22 days ago - By: Pasithea

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

23 days ago - By: Benzinga - Mentions: PACS GNTA SCYX NCNA ...

12 Health Care Stocks Moving In Thursday's After-Market Session

23 days ago - By: Pasithea

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

a month ago - By: Pasithea

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

4 months ago - By: Pasithea

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Pasithea

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

5 months ago - By: Pasithea

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

6 months ago - By: Pasithea

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

6 months ago - By: Pasithea

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

7 months ago - By: Stocktwits

Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

7 months ago - By: Pasithea

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

PASITHEA THERAPEUTICS CORP (KTTA) Stock News

KTTA Latest News, Press Relases and Analysis